These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22536427)

  • 1. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation.
    Hess K; Ajjan R; Phoenix F; Dobó J; Gál P; Schroeder V
    PLoS One; 2012; 7(4):e35690. PubMed ID: 22536427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot.
    Gulla KC; Gupta K; Krarup A; Gal P; Schwaeble WJ; Sim RB; O'Connor CD; Hajela K
    Immunology; 2010 Apr; 129(4):482-95. PubMed ID: 20002787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation.
    Kozarcanin H; Lood C; Munthe-Fog L; Sandholm K; Hamad OA; Bengtsson AA; Skjoedt MO; Huber-Lang M; Garred P; Ekdahl KN; Nilsson B
    J Thromb Haemost; 2016 Mar; 14(3):531-45. PubMed ID: 26614707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
    Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V
    Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MASP-1 Induced Clotting--The First Model of Prothrombin Activation by MASP-1.
    Jenny L; Dobó J; Gál P; Schroeder V
    PLoS One; 2015; 10(12):e0144633. PubMed ID: 26645987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor.
    Shenkman B; Einav Y; Livnat T; Budnik I; Martinowitz U
    Blood Transfus; 2014 Jan; 12(1):78-84. PubMed ID: 24333083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MASP-1 of the complement system promotes clotting via prothrombin activation.
    Jenny L; Dobó J; Gál P; Schroeder V
    Mol Immunol; 2015 Jun; 65(2):398-405. PubMed ID: 25745807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mannose-binding lectin-associated serine protease-1 cleaves plasminogen and plasma fibronectin: prefers plasminogen over known fibrinogen substrate.
    Choudhary K; Patel PK; Are VN; Makde RD; Hajela K
    Blood Coagul Fibrinolysis; 2021 Oct; 32(7):504-512. PubMed ID: 34650023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.
    Standeven KF; Ariëns RA; Whitaker P; Ashcroft AE; Weisel JW; Grant PJ
    Diabetes; 2002 Jan; 51(1):189-97. PubMed ID: 11756340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MASP-1 of the complement system enhances clot formation in a microvascular whole blood flow model.
    Jenny L; Dobó J; Gál P; Pál G; Lam WA; Schroeder V
    PLoS One; 2018; 13(1):e0191292. PubMed ID: 29324883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
    Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
    J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R).
    Bouma BN; Meijers JC
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):13-9. PubMed ID: 14872415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
    Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII.
    Nielsen VG; Kirklin JK
    Blood Coagul Fibrinolysis; 2008 Dec; 19(8):793-800. PubMed ID: 19002046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement lectin pathway components MBL and MASP-1 promote haemostasis upon vessel injury in a microvascular bleeding model.
    Golomingi M; Kohler J; Jenny L; Hardy ET; Dobó J; Gál P; Pál G; Kiss B; Lam WA; Schroeder V
    Front Immunol; 2022; 13():948190. PubMed ID: 36032172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
    Mosnier LO; von dem Borne PA; Meijers JC; Bouma BN
    Thromb Haemost; 1998 Nov; 80(5):829-35. PubMed ID: 9843179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture.
    Jadhav MA; Goldsberry WN; Zink SE; Lamb KN; Simmons KE; Riposo CM; Anokhin BA; Maurer MC
    Biochim Biophys Acta Proteins Proteom; 2017 Oct; 1865(10):1246-1254. PubMed ID: 28687225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2.
    Krarup A; Wallis R; Presanis JS; Gál P; Sim RB
    PLoS One; 2007 Jul; 2(7):e623. PubMed ID: 17637839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
    Grosso G; Vikerfors A; Woodhams B; Adam M; Bremme K; Holmström M; Ågren A; Eelde A; Bruzelius M; Svenungsson E; Antovic A
    Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid: experimental studies in thromboelastometry.
    Koller T; Kinast N; Castellanos AG; Garcia SP; Iglesias PP; Vintro XL; Arranz JM; Seto NV; García MVM; Moreno-Castaño AB; Aznar-Salatti J; Albaladejo GE; Diaz-Ricart M
    Scand J Trauma Resusc Emerg Med; 2021 Apr; 29(1):57. PubMed ID: 33836790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.